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Abscisic acid (ABA) , a long known phytohormone, has been recently demonstrated to be present 
also in humans, where it targets cells of the innate immune response, mesenchymal and hemopoietic 
stem cells and cells involved in the regulation of systemic glucose homeostasis. LANCL2, a peripheral 
membrane protein, is the mammalian ABA receptor. We show that N-terminal glycine myristoylation 
causes LANCL2 localization to the plasmamembrane and to cytoplasmic membrane vesicles, where 
it interacts with the α subunit of a Gi protein and starts the ABA signaling pathway via activation of 
adenylate cyclase. Demyristoylation of LANCL2 by chemical or genetic means triggers its nuclear 
translocation. Nuclear enrichment of native LANCL2 is also induced by ABA treatment. Therefore 
human LANCL2 is a non-transmembrane G protein-coupled receptor susceptible to hormone-induced 
nuclear translocation.
The human genome encodes three distinct LANCL proteins, LANCL1, LANCL2 and LANCL31, which share a 
high structural homology with the lanthionine synthetase component C, a cyclase involved in the synthesis of 
lantibiotics in Prokaryotes2. LANCL3 has been suggested to be a pseudogene3. LANCL1 has been hypothesized 
to be implicated in the metabolism of lanthionine metabolites in the central nervous system4. LANCL2 proved to 
be the human receptor of abscisic acid (ABA)5–10.
ABA, a long-known plant hormone11,12, has been shown to be present also in mammals, where it affects several 
key functions in different cell types9,10,13,14. ABA behaves as a pro-inflammatory modulator of cells of the innate 
immune response7,15–17, stimulates the proliferation of human mesenchymal and hemopoietic stem cells18,19, and 
is involved in the control of systemic glucose homeostasis5,20–24.
LANCL2-mediated ABA signaling in mammals requires a pertussis toxin (PTX)-sensitive G protein5, even-
tually leading to an increase of intracellular Ca2+ levels ([Ca2+]i). The signaling pathway downstream of ABA 
binding to LANCL2 involves the activation of adenylate cyclase (AC), followed by overproduction of cAMP, 
PKA-catalyzed phosphorylation and stimulation of the plasmamembrane-bound ADP-ribosyl cyclase CD38, 
which converts NAD+ to cADPR and ADPR, leading to an increase of both extracellular Ca2+ entry and 
Calcium-induced calcium release (CICR)-mediated intracellular Ca2+ mobilization5,9,15,21.
Several indirect lines of evidence point to a Gi as the G protein coupled to LANCL2: i) the sensitivity of the 
ABA signaling pathway to PTX in human granulocytes and in insulin-releasing cells15,21; ii) the accumulation 
of inositol 1,4,5-P3 (IP3) in human cells co-transfected with LANCL2 and a chimeric G protein, Gα q/i, upon 
stimulation with ABA5, and, iii) inhibition of the ABA-induced cAMP increase in ABA-sensitive human cells by 
overexpression of transducin, a β γ -subunit scavenger5. However, conclusive identification of the nature of the G 
protein coupled to LANCL2 has yet to be provided. For instance, the role of Gβγ in AC signaling is exceedingly 
complex, as witnessed by both AC-activating and inhibiting effects related to wide heterogeneity of the coupling 
receptors and of the various membrane-associated AC isoforms25,26. Moreover, the mechanism of the LANCL2-G 
protein coupling, specifically whether it is direct or mediated by other proteins, remains to be defined.
Interestingly, LANCL2 is not a transmembrane protein, as predicted in silico from its sequence27–29 and con-
firmed in vitro by the observation that it can be removed from the plasmamembrane without the use of deter-
gents, either by mild chemical treatments30 or by inhibition of its post-translational N-terminal myristoylation28. 
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In addition, the non-myristoylated LANCL2-GFP fusion protein has been found to be confined to the nucleus28. 
This observation raises the possibility that its hormone ligand ABA may affect the trafficking of LANCL2 between 
membranes and nucleus.
Indeed, recent findings allow to reconcile the non-transmembrane localization of LANCL2 with its hormone 
receptor function, as the human anion exchanger AE1 has been shown to mediate ABA transport across the 
plasmamembrane30.
Here, we investigated the unusual features of LANCL2 among G protein-coupled animal hormone receptors 
(GPCR), by means of site-directed mutagenesis and of confocal fluorescence microscopy, fluorescence recov-
ery after photobleaching (FRAP) and photoactivation techniques. The localization, the intracellular mobility of 
LANCL2 in the presence of ABA and its interaction with Gi were explored.
Results
Role of N-terminal myristoylation in the subcellular localization of untagged LANCL2. Comparison 
between the three LANCL genes shows that Met 19 of LANCL2 is aligned with the start methionine of the highly 
homologous LANCL1 and LANCL3 (Supplementary Table 1), which are cytosolic proteins27–29. Thus, transcription 
of LANCL2 starting from Met 19 would result in a shorter protein, lacking the myristoylated glycine and the 18-ami-
noacids N-terminal stretch (LANCL2sh).
Supplementary Fig. 1 shows a representative Western blot of full length LANCL2 from HeLa, HEK and the 
human adenocarcinoma cell line MDA-MB-468 (MDA-468), revealed with a specific mAb (see Materials and 
Methods). In this cell line, a 0.9 Mb region, containing the LANCL2 gene, is amplified31. Overexpression of 
LANCL2 in MDA-468 cells was documented by microarray profile analysis, by RT-PCR and by measuring [3H]
ABA binding to intact cells, in comparison with the MDA-MB-231 (a breast adenocarcinoma cell line not over-
expressing LANCL2)32. The Bmax values calculated from the relevant saturation curves by Scatchard plot analysis 
were 0.70 pmol ABA/mg protein for MDA-468 and 0.023 pmol ABA/mg protein for MDA-231, respectively.
Landlinger et al.28 demonstrated that GFP-fused LANCL2 overexpressed in human amniotic epithelial cells 
was associated with the plasmamembrane; moreover, inhibition of myristoylation either by mutation of the 
N-terminal glycine or by incubation of the cells with the specific myristoyl transferase inhibitor 2-hydroxymyristic 
acid (HMA, ref. 33) led to the nuclear localization of the fusion protein.
The fact that in these experiments overexpressed LANCL2 was fused to GFP suggested to verify whether sim-
ilar results could be observed with the untagged protein. In addition, the role of the N-terminal 18 aminoacids in 
the subcellular localization of untagged LANCL2 was investigated by confocal fluorescence microscopy, as this 
technique allows to study protein localization in live cells, in real time and with a high sensitivity.
Therefore, HeLa and HEK cells were transiently transfected with various forms of LANCL2 protein: LANCL2 
fused to EGFP (LANCL2-GFP), untagged LANCL2, G2A mutagenized LANCL2 (LANCL2-G2A), G2A muta-
genized LANCL2 fused to EGFP (LANCL2-G2A-GFP), and short LANCL2 fused to EGFP (LANCL2sh-GFP) 
(Supplementary Table 1).
As shown by the confocal microscope experiments, illustrated in Fig. 1, in HeLa cells, LANCL2-GFP 
co-localized with a myristoylated plasmamembrane marker (Fig. 1A–C), obtained by expressing the red fluores-
cent protein fused to the myristoylation/palmitoylation sequence from Lck tyrosine kinase (Molecular Probes, 
USA). In Fig. 1D, untagged wild-type LANCL2 was revealed with a specific mAb30, showing the plasmamem-
brane localization of LANCL2 also in the absence of tags.
To investigate the effect of de-myristoylation on LANCL2 localization, HEK cells transiently overexpressing 
LANCL2-GFP were incubated without (control, Fig. 1E) or with 1 mM HMA (Fig. 1F)33,34. After 24 hours, most 
of the protein in the HMA-treated cells localized to the nucleus (Fig. 1F) in agreement with previous results28, but 
not in the nucleoli, in contrast with what previously observed.
The nuclear localization of non-myristoylated LANCL2 was confirmed in HeLa expressing untagged LANCL2 
treated with HMA and stained with the anti-LANCL2 mAb (Fig. 1G), as well as in cells expressing either mutag-
enized non-myristoylatable LANCL2-G2A-GFP (Fig. 1H) or untagged LANCL2-G2A (Fig. 1I).
Therefore, no substantial localization differences were observed between various GFP-tagged and untagged 
LANLC2 recombinant forms (Supplementary Table 1), both in HeLa and in HEK cells. Specifically, while full 
length myristoylated LANCL2 localized to the plasmamembrane and to cytoplasmic sites (Fig. 1A–E), loss of 
the myristoyl anchor due to chemical (HMA) or genetic (G2A) inhibition of myristoylation led to the nuclear 
localization of both the GFP-tagged (Fig. 1F,H, respectively) and the untagged proteins (Fig. 1G,I, respectively).
Accordingly, we explored the presence of nuclear localization signals (NLS) in LANCL2. The cNLS Mapper, a 
software predictor of NLS35, identified two potential NLS sequences in the N-terminal region of LANCL2, with a 
similar score of 3.6/10: a monopartite NLS (T4-H12) and a bipartite NLS (K7-G37). Indeed, LANCL2-G2A-GFP 
localized predominantly into the nucleus (Fig. 1H), whereas the truncated form LANCL2sh-GFP, which lacks 
the N-terminal peptide containing the NLS, showed a homogeneous distribution throughout the cell (Fig. 1L).
Effects of myristoylation on the intracellular mobility of LANCL2. In order to investigate LANCL2 
mobility in live cells, we exploited two different techniques that require the use of fluorescently tagged proteins: 
fluorescence recovery after photobleaching (FRAP) and fluorescence decay after photoactivation (FDAP).
FRAP explores the mobility of the tagged protein by analyzing the recovery of the fluorescent signal in a 
specific region of interest (ROI) after permanent photobleaching36. To this purpose, HeLa cells were transiently 
transfected with the full length LANCL2-GFP or with the truncated LANCL2sh-GFP form, and FRAP experi-
ments were performed 48 h after transfection. ROIs were selected in a cytoplasmic area of the cells close to the 
plasmamembrane avoiding the Golgi and nuclear areas (Fig. 2A).
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The average t½ calculated for LANCL2-GFP was significantly higher than the t½ of LANCL2sh-GFP (3.9 ± 0.9 
s and 1.6 ± 0.2 s for LANCL2-GFP and LANCL2sh-GFP, respectively, graph in Fig. 2A; n = 20 cells from three 
different transfection experiments, p < 0.001).
Then, we also performed photoactivation experiments on LANCL2 fused to photoactivatable GFP (PAGFP). 
To compare the mobility of wild-type LANCL2 with the non-myristoylatable G2A-mutagenized LANCL2, we 
transiently expressed LANCL2-PAGFP or LANCL2-G2A-PAGFP in HeLa cells, and photoactivated a circular 
cytosolic ROI chosen next to the plasmamembrane, in cells of similar shape.
Images acquired at the same time points after photoactivation clearly indicated that the fluorescence decay of 
LANCL2-PAGFP was much slower than that of LANCL2-G2A-PAGFP (Fig. 2B), as confirmed by calculation of 
the half time of recovery (t½), after fitting values to one phase decay curves37: t½ values of LANCL2-PAGFP and of 
LANCL2-G2A-PAGFP were 50 ± 30 s and 3.4 ± 0.75s, respectively (graph in Fig. 2B; = 34 cells from four different 
transfection experiments, p < 0.001).
Moreover, as shown in Supplementary Fig. 2, LANCL2 is capable of rapid lateral diffusion within the 
plasmamembrane.
Together, these observations indicate that the full length LANCL2 is membrane-associated also in the cyto-
plasm. When protein myristoylation was prevented by single point mutation, association with the cell membranes 
was lost, as indicated by its faster free diffusion inside the cell.
Figure 1. Subcellular localization of overexpressed LANCL2 proteins. HeLa (A–D,G–L) or HEK (E,F) 
cells 48 h after transient tranfection with differently tagged LANCL2 forms (Supplementary Table 1). HeLa 
cells co-transfected with (A) LANCL2-GFP and with (B) CellLight™ plasmamembrane-RFP, which showed 
co-localization at the plasmamembrane and juxta-nuclear membrane vesicles in merge panel (C). (D) The 
plasmamembrane localization of overexpressed untagged LANCL2 was revealed with monoclonal anti-human 
LANCL2 mouse antibody (mAb). (E) HEK cells overexpressing LANCL2-GFP. Unlike the membrane protein 
localization of panel (E), both the LANCL2-GFP (F) and the untagged LANCL2 (panel G, LANCL2 revealed 
with the mAb) lost their membrane localization after treatment with 1 mM of the myristoyl tranferase inhibitor 
HMA, resulting in an extensive nuclear localization. The non-myristoylatable G2A mutant LANCL2 form 
showed a similar localization pattern, not only when fused to EGFP (H), but also when stained with mAb 
(untagged mutagenized LANCL2, I). Conversely, if the first 18 amino acids were removed, the protein still lost 
its membrane localization, but shifted to a completely soluble, freely diffusible pattern (L).
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LANCL2 dynamics after ABA treatment. The fact that untagged LANCL2 localized to the cell nucleus 
when not myristoylated (Fig. 1G–I) suggested to explore whether nuclear translocation of the protein might 
occur as part of its signaling pathway, following ABA binding. To investigate whether LANCL2 migrated into 
the nucleus following addition of ABA, we used the full-length form of LANCL2 fused to PAGFP; the finding 
that LANCL2-GFP and untagged LANCL2 behaved similarly in their nuclear localization upon G2A mutation 
(Fig. 1H,I, respectively), was taken as a demonstration that the GFP tag did not significantly modify the intrinsic 
ability of LANCL2 to migrate into the nucleus.
At 48 h after transfection with LANCL2-PAGFP, HeLa cells of similar shape and size were subjected to pho-
toactivation in a 8 μ m-diameter cytoplasmic ROI, with or without (control) the simultaneous addition of 5 μ M 
ABA; the photoactivation ROI was chosen close to the plasmamembrane, 10–20 μ m far from the nearest nuclear 
membrane, whereas the nuclear ROI covered most of the nuclear area (Fig. 3A). The fluorescent signal from 
LANCL2-PAGFP rapidly distributed away from the photoactivated region, slowly increasing also inside the 
nucleus; the dynamics were recorded for 25 min, when a steady-state level of nuclear fluorescence was reached 
(Fig. 3B, left panel).
At 25 min after photoactivation, the mean nuclear fluorescence, relative to the pre-photoactivation frames, was 
significantly higher in the ABA-treated cells compared with untreated controls (4.18 ± 1.4 vs. 2.51 ± 0.5, respec-
tively, n = 22 cells from three different transfection experiments, p = 0.005).
Compared with the nuclear enrichment of LANCL2-PAGFP in the absence of ABA, that of PAGFP alone, 
used as a control, showed a quantitatively similar increase (the plateau of nuclear fluorescence relative to 
pre-stimulation values was 2.2 ± 0.3), but significantly different kinetics (t½ of 2.2 ± 0.4 and 6.6 ± 1.3 min for 
Figure 2. Intracellular mobility of different recombinant forms of LANCL2. (A) A representative FRAP 
experiment. EGFP signal in HeLa cells overexpressing LANCL2-GFP (left column) or LANCL2sh-GFP (right), 
before (prePB) and at indicated time points after photobleaching (T0). Graph: kinetics of mean FRAP, with 
s.d., of LANCL2-GFP (blue) and of LANCL2sh-GFP (red trace); the mean half-life constants are indicated in 
the abscissa as dotted lines. (B) A representative FDAP experiment. PAGFP signal in HeLa cells overexpressing 
LANCL2-PAGFP (left column) or LANCL2-G2A-PAGFP (right), before (prePA) and at different time points 
after photoactivation (T0). Graph: kinetics of mean FDAP, with s.d., of LANCL2-PAGFP (blue) and of 
LANCL2-G2A-PAGFP (red trace); the mean half-life constants are indicated in the abscissa as dotted lines.
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PAGFP and LANCL2-PAGFP, respectively, p < 0.001; Supplementary Fig. 3). Thus, the slight increase of nuclear 
fluorescence of LANCL2-PAGFP in the unstimulated cells could be due to a low extent of ABA-independent, 
spontaneous, LANCL2 nuclear migration, rather than to non-specific nuclear import of a PAGFP-tagged 
protein38.
Analysis of the decaying fluorescence in the cytoplasmic photoactivated ROI revealed a greater LANCL2 
decrease in the ABA-treated than in the untreated cells: the plateau of the fluorescence values relative to the first 
photoactivated frame and fitted to a single exponential curve, was 0.32 ± 0.09 for control, and 0.22 ± 0.076 for 
ABA-treated cells (n = 17 cells, p < 0.001; Fig. 3B, right panel). Moreover, the fluorescence decay in the photo-
activated cytoplasmic ROI was faster in ABA-treated compared with control cells (the half-life was 50 ± 30 s for 
control, and 23 ± 13 s for ABA-treated cells; n = 17 cells, p = 0.02).
The higher nuclear content of LANCL2 in the ABA-treated cells, in agreement with the greater and faster 
LANCL2 decrease in the cytoplasmic photoactivation region, indicates that ABA stimulates LANCL2 migration 
into the nucleus.
Role of localization on LANCL2 function. Next, we investigated the role of the myristoylation-dependent 
membrane localization of LANCL2 in ABA perception/signaling.
ABA binding to LANCL2 eventually results in the stimulation of AC mediated by the β γ subunit complex 
released from an activated Gi-protein5.
To determine whether LANCL2 directly interacted with the α subunit of a Gi-protein, we performed FRET 
experiments, by labelling LANCL2 with a donor fluorophore (EGFP) at the C-terminus (LANCL2-GFP), and the 
α subunit of a chimeric Gi protein, known to be activated by LANCL25, with an acceptor fluorophore (TagRFP, 
Gi-RFP). As a negative, non membrane-associated control, we used the EGFP-tagged soluble short form of 
LANCL2, LANCL2sh-GFP (Supplementary Table 1).
Co-transfection of LANCL2-GFP and Gi-RFP in HeLa cells generated a measurable FRET signal, indicating 
that the donor (EGFP) and the acceptor (TagRFP) were sufficiently close to allow resonance energy transfer 
(Fig. 4A–C). Interestingly, FRET between LANCL2 and the Gi α subunit was observed not only on plasmam-
embranes (identified by their intense signal at the border of the cells, and analyzed by manually drawn ROIs), 
but also in intracellular regions: the average apparent FRET efficiency calculated for the LANCL2-Gi couple in 
plasmamembrane ROIs (20 ± 7%) was similar to the FRET calculated in whole-cell regions (20 ± 5%; n = 40 cells 
in five different transfection experiments, Fig. 4G). Conversely, the interaction was lost (FRET efficiency 1 ± 2%) 
when the Gi-RFP was co-transfected with soluble LANCL2sh-GFP (Fig. 4G).
According to these results, we can infer that the interaction with the α subunit of the chimeric Gi-protein 
requires a membrane-associated, myristoylated, LANCL2, the close proximity between LANCL2 and Gi occur-
ring both on the plasmamembrane and on intracellular membranes.
Figure 3. ABA-stimulated LANCL2 nuclear import. (A) Representative images of unstimulated HeLa cells 
transfected with LANCL2-PAGFP, immediately following photoactivation (T0), 25 minutes later and in bright 
field. ROIs of cytosolic photoactivation (round) and of nuclear analysis (oval) are drawn; a squared ROI, for 
background fluorescence correction, is indicated on bright field panel (right). (B) Graphs: analysis of mean 
fluorescence increase over time in nuclear ROIs (left), and of fluorescence decay in photoactivated cytoplasmic 
ROIs (right). HeLa cells were treated (+ ABA, red trace) or not (LANCL2-PAGFP, blue trace) with 5 μ M ABA, 
immediately before photoactivation.
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We then compared the ABA-binding ability of purified recombinant LANCL2 (LANCL2-gst) and of its trun-
cated short form (LANCL2sh-gst). Both forms were cleaved from the GST tag (Supplementary Table 1), produced 
as described in6, but cleaved in the absence of DTT, a more physiological condition leading to a higher binding 
affinity than previously observed. Indeed, specific and saturable [3H]ABA binding occurred to both proteins with 
similar affinities (Kd values were 8.9 ± 1 μ M and 10.6 ± 1.4 μ M for LANCL2 and LANCL2sh, respectively, from 
three different experiments).
Thus, the 18 aminoacids N-terminal stretch of LANCL2, which includes the myristoylation site, is not neces-
sary for ABA binding.
Finally, we explored the ability of different LANCL2 forms to trigger the ABA-signaling pathway, by measur-
ing the increase of the intracellular concentration of cAMP ([cAMP]i) in transfected HeLa cells following addi-
tion of ABA (as described in15).
HeLa cells transfected either with untagged LANCL2, or with LANCL2-GFP, or with the untagged mutage-
nized LANCL2 (LANCL2-G2A) were incubated with 5 μ M ABA and the [cAMP]i was measured after 30 s. The 
[cAMP]i increased in HeLa cells overexpressing untagged LANCL2 (165 ± 19% over basal, unstimulated values, 
p < 0.02) or LANCL2-GFP (170 ± 21%, p < 0.02). Conversely, the [cAMP]i was not significantly modified com-
pared to basal values in cells transfected with the non-myristoylatable LANCL2-G2A (94 ± 17%, p = 0.6), Fig. 4H.
Therefore, LANCL2 myristoylation and a functional interaction between LANCL2 and the chimeric Gi α sub-
unit (Fig. 4H) are essential for the ABA-triggered activation of adenylate cyclase, both requirements being met at 
the plasmamembrane and at internal membranes in the cytoplasm.
Conversely, binding of ABA does not require association of LANCL2 with the plasmamembrane, as it is not 
significantly affected by the truncation of 18 N–terminal aminoacids. This observation suggests that an unmyris-
toylated, and thus freely-diffusible, LANCL2 could be able to bind ABA and activate other, cAMP-independent, 
signaling pathways.
Discussion
Here, we demonstrated that N-terminal glycine myristoylation causes LANCL2 localization to the plasmam-
embrane and to cytoplasmic membrane vesicles as well. Interestingly, evidence has recently been provided of 
Figure 4. Physical and functional interaction of myristoylated LANCL2 with Gi-protein. FRET analysis 
between LANCL2-GFP (A–C) or LANCL2sh-GFP (D–F), and Gi-RFP, in HeLa cells. Representative images of 
emission of excited donor (GFP-fused proteins: A,D), of excited acceptor (G-RFP: B,E), and of measured FRET 
efficiency (C,F) are shown in Leica software pseudo colours. Plasmamembrane ROIs are drawn in upper panel, 
and whole-cell ROIs are shown in lower panel, respectively. (G) Graph: the average FRET efficiency between 
LANCL2 and Gi-protein was not significantly different when calculated in plasmamembranes (LANCL2-G pm) 
or in intracellular compartments (LANCL2-G cell). Negligible FRET values were measured between soluble 
LANCL2sh-GFP and G-protein (LANCL2sh-G). (H) HeLa cells were transfected with untagged LANCL2 
(LANCL2), GFP-tagged LANCL2 (LANCL2-GFP) or untagged mutagenized G2A LANCL2 (LANCL2-G2A). 
After 48 h from transfection, cells were challenged with 5 μ M ABA, and processed for measurement of [cAMP]i 
levels after 30 s, as described in15. Results are expressed as pmol cAMP/106 cells, in untreated (light gray bars) or 
ABA-stimulated (dark gray bars). *p < 0.02, relative to control, by t test.
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non-canonical subcellular sites for G protein activation: these include endosomal localization of functionally 
active GPCR39–41, and the interaction of the GIV/Girdin protein, a non-receptor guanine nucleotide exchange 
factor, with heterotrimeric G proteins at the Golgi42,43 and at still undefined intracellular sites44. The effectiveness 
of N-myristoylated LANCL2 in coupling to Gi physically and functionally (FRET efficiency and [cAMP]i increase, 
Fig. 4) also when associated to internal membrane vesicles represents a further example of G-protein mediated 
signal initiation at non-canonical intracellular sites.
The finding of nuclear localization of LANCL2 after exposure of the cells to ABA (Fig. 3) suggests a possible 
role for LANCL2 in ABA-triggered transcriptional events. Indeed, stimulation by ABA of the transcription of 
several cytokines regulating the proliferation of human mesenchymal and hemopoietic stem cells has been previ-
ously observed18,19, and ABA-induced transcriptome variations are well established in plants45.
A still unanswered question is whether demyristoylation of native LANCL2 (e.g., via specific enzymes or 
limited proteolysis targeting the N-terminus) is required for nuclear import and whether ABA binding itself can 
boost demyristoylation. So far, we were unable to identify any demyristoylated form of LANCL2, which could 
however escape detection for several reasons (e.g., transient nature due to rapid nuclear clearance, or low speci-
ficity of anti-myristoyl anchor antibody).
The facts that LANCL2 is intracellular and that its hormone ligand ABA is an anion at physiological pH values, 
and thus unable to diffuse across the membrane lipid bilayer, imply that a transmembrane transport is required 
to allow extracellular ABA to reach its receptor. Indeed, influx of ABA has been recently demonstrated to occur 
through the transmembrane bicarbonate/chloride exchanger 1 (AE1, band 3 protein) in erythrocytes30. Moreover, 
the bidirectional nature of ABA transport across the plasmamembrane may also support paracrine mechanisms, 
already observed with this hormone9,10,17–19,21,22, based upon release of ABA from one cell and its perception/sig-
naling in a neighboring cell. In any case, the fact that ABA enters the cells through a transmembrane transporter 
is unique among animal hydrophilic hormones, which bind to the extracellular domain of integral membrane 
receptors.
In conclusion, this study highlights some non-canonical features of the mammalian ABA receptor: i) LANCL2 
is a membrane-bound, but not an integral membrane protein, whose myristoylation allows coupling to a Gi pro-
tein and activation of adenylate cyclase; ii) upon ABA-binding LANCL2 can translocate into the nucleus, to our 
knowledge an unprecedented feature for a membrane-associated, G-protein coupled, receptor.
The diversified LANCL2 intracellular behavior might account for the emerging multifunctionality of 
LANCL246, for the heterogeneity of cell targets and for the pleiotropy of ABA-stimulated regulatory effects in 
these cells, impacting on fundamental systemic functions7–10,15–19,47.
These results broaden our knowledge on the mechanisms underlying hormonal receptor-G protein interac-
tion in animals, by providing the first observation of a non-transmembrane G protein-coupled receptor capable 
of hormone-induced nuclear translocation. Thus, LANCL2 appears to be uniquely endowed with two key features 
(G protein-coupling and nuclear translocation), each one typical of a different family of animal hormone recep-
tors, i.e. peptide and steroid hormone receptors, respectively.
Conservation of ABA as a stress hormone regulating cell responses to environmental stimuli in plants, lower 
Metazoa (sponges and hydroids)48,49 and mammals, suggests its origin in a common precursor to animals and 
plants. This ancient evolutionary root may indeed place this hormone in a category of its own compared to the 
other animal hormones.
Materials and Methods
Reagents and antibodies. The mouse monoclonal antibody against human LANCL2 (LANCL2 mAb) was 
produced by Dr. C. Fresia at Molecular Biotechnology Center (MBC), Turin (Italy), as previously described30. 
Primary antibody anti-human vinculin was a kind gift of E. Turco (MBC, Turin). HRP-conjugated second-
ary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA); Alexa-488-conjugated ones were from 
Thermo Fisher Scientific (NY, USA). 2-hydroxymyristic acid (HMA), tissue culture media and supplements were 
purchased from Sigma-Aldrich (Milan, Italy). HMA, dissolved in chloroform and dryed out with N2, was resus-
pended at a 10 mM concentration in 1% fatty acid free BSA in HBSS, through overnight shaking33,34.
Cell cultures and transfection. HeLa, HEK-293, MDA-MB-468, MDA-MB-239 cells were cultured in 
Dulbecco’s modified Eagle’s complete cell culture medium (DMEM with 10% fetal bovine serum, 50 U/ml pen-
icillin, 50 μ g/ml streptomycin). Cells were seeded at 15.000/cm2, on 25 mm glass coverslip Menzel-Glaser thick-
ness N1.5 (Tecnovetro SRL, Monza, Italy), on 8-wells chambered coverglasses (Lab-Tek, Nunc, Thermo Fisher 
Scientific, NY, USA), or on 35 mm Petri dishes 24 hours before transfection, and maintained in a humidified 5% 
CO2 atmosphere at 37 °C.
Cells were transfected with the calcium-phosphate method50, adding to the fresh complete medium a 10% 
volume of transfection reagent composed of Hepes Buffered Saline, 100 mM CaCl2 and 30 μ g/ml endotoxin-free 
DNA (prepared with EndoFree Plasmid Midi Kit, QIAGEN, following manufacturer instructions). Medium was 
replaced after 12–16 h.
The ready-to-use construct CellLight® Plasma Membrane-RFP (Molecular Probes, Thermo Fisher Scientific, 
Waltham, MA USA) was transfected into cells 24 h after LANCL2-GFP transfection, using BacMam 2.0 technol-
ogy; it was obtained by expressing the red fluorescent protein (RFP) fused to the myristoylation/palmitoylation 
sequence from Lck tyrosine kinase, providing accurate and specific targeting to cellular plasmamembrane.
Western Blot. Western blot analyses were performed following standard methods, as previously described28: 
5–50 μ g of different cell lysates (1% SDS, 5 mM EDTA, 10 mM DTT, 1:200 of protease inhibitors cocktail, 
Sigma-Aldrich) were loaded on a 10% polyacrylamide gel.
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Recombinant proteins and [3H]ABA binding. Expression and purification of the recombinant proteins 
were performed as previously described5. BL21 (DE) E. coli cells utilized were grown in Luria–Bertani medium 
(Difco, BD Italia, Roma, Italy).
The release of LANCL2-gst or of LANCL2sh-gst (Supplementary Table 1) was achieved with the PreScission 
Protease (GE Healthcare), by incubating the GSH-Sepharose-bound fusion protein for 16 h at 4 °C following 
manufacturer instruction, but without DTT: the protease cleavage left 9 amino acids at the N-terminus of the 
protein, considered in the Mw calculations.
To compare specific [3H]ABA binding of recombinant LANCL2-gst and LANCL2sh-gst produced in E. coli, 
we proceeded as previously described in6.
[3H]ABA binding experiments to intact MDA-MB-468 and MDA-MB-231 cells, were performed as previously 
described in15.
Immunofluorescence and fluorophores. HeLa or HEK-293 cells were grown on 18- or 25-mm diam-
eter coverslips, previously coated with poly-L-lysine (Sigma-Aldrich), for 24 hours before transfection, 2-HMA 
treatment or fixation. Specimens were treated for fixation at RT for 10 min with para-formaldehyde (4% in PBS), 
then permeabilized for 8 min with 0.1% Triton X100, blocked for 10 min with 3% BSA, incubated for 1 hour with 
anti-LANCL2 mAb 5 μ g/ml in BSA 3%, and finally stained for 30 min with 10 μ g/ml Alexa Fluor 488 secondary 
antibody (Thermo Scientific). Mounting medium was Mowiol + 2.5% DABCO (Sigma-Aldrich).
For live analysis cells were maintained in complete DMEM without phenol red, supplemented with 20 mM 
Hepes.
Excitation/emission maxima of fluorophores utilized were: Alexa 488 495/519, EGFP 488/507, PAGFP 
504/517, TagRFP and CellLight® -RFP 555/584.
Localization images were obtained using a Leica TCS SP2 confocal microscope (Leica Microsystem, 
Heidelberg, Germany) equipped with argon/He-Ne laser sources and Leica HCX PL APO CS 63.0 X N.A1.40 oil 
objective.
To exclude that the EGFP-fusion could affect subcellular distribution, we treated HeLa cells overexpressing 
untagged LANCL2 with the N-myristoyl transferase inhibitor 2-hydroxymyristic acid (HMA), then stained the 
protein with a specific anti-LANCL2 mAb; as a further control to ensure that no intracellular morphological 
changes affecting LANCL2 localization could have been induced by the HMA treatment51,52, we used the mutag-
enized form of LANCL2 bearing the G2A mutation (therefore not susceptible to undergo myristoylation), fused 
to EGFP.
cDNA constructs. cDNA encoding human LANCL2 was subcloned from previously available constructs6 
into the following expression vector: pEGFP-N, pcDNA3.1+, pPAGFP-N1, pGEX-6P-1. When compatible, 
restriction enzyme sites were used for subcloning; otherwise, and for truncated LANCL2 forms (LANCL2sh-gst, 
LANCL2sh-GFP), specific primers containing the desired restriction enzyme sites were designed for PCR ampli-
fication from plasmid (TibMolBiol, Genova, Italy). The G2A site-specific mutagenesis was obtained with the 
QuickChange Lighting Site-Directed Mutagenesis kit (Agilent Technologies; Santa Clara, CA), following manu-
facturer’s instructions, applied on the corresponding/analogous/appropriate vector.
EGFP and PAGFP tags were fused at the C-terminus of LANCL2 protein forms.
The EGFP coding sequence contained an A207K mutation to eliminate potential dimerization of the EGFP 
moiety53.
The α subunit of the chimeric Gi protein5 was subcloned into pTagRFP-C (Evrogen, Moscow, Russia), thus 
resulting N-terminally fused to TagRFP monomeric protein.
All cDNA constructs (Supplementary Table 1) were confirmed by sequencing (TibMolBiol).
FRAP and photoactivation experiments. HeLa cells were transiently transfected with LANCL2-GFP or 
LANCL2sh-GFP for FRAP experiments, or with LANCL2-PAGFP or LANCL2-G2A-PAGFP for FDAP experi-
ments, and processed 48 h after transfection. Images were acquired by a Nikon A1 confocal microscope (Nikon 
Corporation, Tokio, Japan), equipped with a 60 X PlanApo oil immersion objective (NA 1.40). All images, cor-
rected for fluorescence background, were analysed with ImageJ 1.48v (Wayne Rasband, Nat. Inst. of Health, 
USA), and the obtained data with the Excel software (Microsoft).
For FRAP experiments, the EGFP fluorescence emission was bleached in a 6 μ m-diameter ROI for 0.12 s, with 
the 405 nm laser line, zooming to the ROI to minimize the photobleaching duration54. Fluorescence recovery was 
followed for 120 s, exciting the sample with the 488nm Argon Laser-line.
At each time point the mean fluorescence value (Ft) in the bleached ROI was analysed as described37,55: each 
ROI Ft was normalized for the Ft of a ROI not subjected to photobleaching, to correct for photobleaching of EGFP 
due to the imaging procedure. Photobleaching-corrected Ft values were subtracted of first post-photobleaching 
values and normalized for the mean fluorescence value measured before photobleaching.
Fluorescence recovery traces were fitted with a single exponential equation (GraphPad Prism, version 5.01 for 
Windows, California, USA), as follows:
= − − τF F (1 e )tt max
/
which allowed to calculate the half-time constant (t½), the time it takes for the fluorescence to recover to 50% of 
the asymptote (plateau) intensity (Fmax), as t½  = τ *ln2.
For each experimental condition, all curves were averaged and t½ values of different populations were com-
pared using Student’s t-test.
ROIs of different size were analyzed, yielding similar results.
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Photoactivation was performed by exciting the PAGFP with the 405 nm laser line inside a 8 μ m-diameter 
ROI for 0.063 s. The fluorescence decay in the photoactivated region was imaged for 3 min for fast-diffusing 
LANCL2-G2A-PAGFP, and for 25 min for LANCL2-PAGFP, with 488nm laser line.
As control, we used PFA-fixed HeLa cells expressing LANCL2-PAGFP to monitor the potential photobleach-
ing of PAGFP during the observation time.
No bleaching was observed in fixed cells in the time interval of our experiments, nor in ROIs chosen in living 
transfected HeLa cells after whole-cell photoactivation (data not shown).
After photoactivation, the mean fluorescence value (Ft) of the ROI at each time point was corrected for the 
fluorescence measured before the photoactivation; then it was normalized to Ft0, where t0 is the first frame after 
the photoactivation.




⁎F (F F ) e Ft t0 t
t/
t
where Ft∞ is the normalized fluorescence value at infinite time. The half-life (t½) for each experimental condition 
was averaged, and the different populations were compared using Student’s t-test.
FRET imaging and analysis. Fluorescence (or Förster) Resonance Energy Transfer (FRET) allows the 
study of protein interactions, measuring a non-radiative transfer of energy from an excited state or a fluorophore 
(donor) to a different fluorophore (acceptor), over distances comparable to the size of proteins56,57. As stated by 
the non-invasive method of sensitized emission (SE) applied to live specimens, following donor excitation, FRET 
results in a decrease in donor emission with a simultaneous increase in acceptor emission, due to a dipolar inter-
action between the molecules58.
The expression of EGFP and TagRFP tagged proteins in HeLa cells grown in 8-wells chambered coverglasses 
(Lab-Tek, Nunc, Thermo Scientific) was visualized 2 days after transfection by confocal microscopy using a Leica 
TCS SP5 AOBS (Leica Microsystem, Heidelberg, Germany) equipped with an oil immersion objective 63x/1.4 
NA. Light collection configuration was optimized according to the combination of chosen fluorochromes, select-
ing the spectral windows by the acousto-optic beam splitter of the Leica SP5 scanning head.
The Leica “LAS AF” software package was used for image acquisition. FRET efficiency (FE) was measured 
using the Sensitized Emission method57. Briefly, measurements were performed by detection of the fluorescent 
signals of the donor, FRET and acceptor in a line by line sequential scan acquisition, obtained with the Leica 
Microsystem “FRET SE Wizard” software. The same process was applied to donor-only and acceptor-only ref-
erence specimens, on cells chosen to visually display mean fluorescence intensity. From the images obtained, we 
calculated the calibration coefficients required to correct for excitation and emission crosstalk.
FE was calculated in plasmamembrane-representing or in whole-cell-including ROIs, for 8–15 cells in each 
experiment, according to FE = (B − β A − γ C)/C, where A, B, C are the intensities of the donor, FRET and accep-
tor emissions and β and γ are the calibration factors correcting for donor cross-talk and acceptor cross-excitation, 
respectively.
Statistical Analysis. Data were compared using an unpaired Student’s t test. Statistical significance was 
set at P-value < 0.05. Statistical analysis was performed using the GraphPad Prism Software, or Microsoft Excel 
software.
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